On 31 July 2020 CLINUVEL Pharmaceutical Limited (ASX:CUV) reported its 4Q FY20 update.
In the fourth quarter of FY20, cash flow remained positive, and CLINUVEL has A$66.747 million cash at hand rise of A$4.42 million.
During this quarter, CLINUVEL recorded cash receipts of A$10.4 million. Despite the ongoing COVID-19 pandemic, CLINUVEL has extended access to SCENESSE® during FY20.
Cash and equivalents of the company rose by 7% over the quarter.
Subsequent to SCENESSE® approval in Europe and the US, CLINUVEL is pursuing approvals for EPP in other regions, and the decision is anticipated from the TGA by the end of CY20.
There is no investor left unperturbed with the ongoing trade conflicts between US-China and the devastating bushfire in Australia.
Are you wondering if the year 2020 might not have taken the right start? Dividend stocks could be the answer to that question.
As interest rates in Australia are already at record low levels, find out which dividend stocks are viewed as the most attractive investment opportunity in the current scenario in our report.